Drugs / Torvutatug samrotecan
Torvutatug samrotecan
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07402915 | Jan 2026 → Oct 2027 expected | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05797168 | Jun 2023 → Aug 2028 expected | endometrial cancer, lung adenocarcinoma, ovarian cancer, squamous cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07816666 | Sep 2026 → Sep 2028 expected | fallopian tube cancer, primary peritoneal carcinoma | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07851025 | Sep 2026 → Jun 2030 expected | malignant epithelial tumor of ovary | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07218809 | Dec 2025 → Nov 2028 expected | ovarian epithelial tumor | AstraZeneca | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-03 | AstraZeneca | Results AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 astrazeneca.com ↗
A poster presentation sharing dose escalation results from the FONTANA Phase I/IIa first-in-human trial of AZD5335 demonstrating clinical activity, favourable pharmacokinetic and manageable safety profiles in patients with platinum-resistant recurrent ovarian cancer. |
| 2023-04-14 | AstraZeneca | Results AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗
A robust anti-tumour response is reported in FRα-expressing preclinical models that are resistant to another FRα ADC with a microtubule inhibitor warhead. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-03 | AstraZeneca | AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 astrazeneca.com ↗ |
| 2023-04-14 | AstraZeneca | AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Torvutatug samrotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05797168 ↗ |
| Known as | AZD5335 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07218809 ↗ |
| Known as | Torvu-sam | “The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as...” NCT07816666 ↗ |
| Action | Inhibit | “the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335” NCT07402915 ↗ |
| Modality | Other / unclassified | “IV Antibody-drug conjugate” NCT05797168 ↗ |
| Route | Intravenous | “IV Antibody-drug conjugate” NCT05797168 ↗ |